Most AI drug development firms are focused on discovery. AI biotech Formation Bio is betting the real bottleneck is clinical trials. With a new $600 million fund to buy or license potential drugs that have stalled out, the startup now hopes to prove that it’s right. (To get the Forbes weekly InnovationRx newsletter in your inbox, [ subscribe here ]( " .)
Forbes ·